LYELL IMMUNOPHARMA IN

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

29 3 2022 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

08 3 2022 15:45:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

31 1 2022 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

24 1 2022 07:00:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

04 1 2022 15:05:01 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

16 12 2021 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

15 12 2021 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair

02 12 2021 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

12 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

08 9 2021 15:05:00 提供 Nasdaq GlobeNewswire

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

12 8 2021 15:05:02 提供 Nasdaq GlobeNewswire